Background: The amount of tissue resection, measured in weight per breast, in breast reduction surgery has been considered a potential risk factor for complications.
Objective: We aimed to evaluate the effect of removing >1000 g versus <1000 g of breast tissue in women with macromastia.
Methods: A systematic search was performed on Pubmed, Embase, and Cochrane in March 2024 for studies that compared resection weight >1000 g versus <1000 g in reduction mammoplasty. Pooled odds ratios were computed for binary endpoints. We used R Studio for statistical analysis.
Results: We included 8 studies, with 1760 breasts, among which 493 (28.1%) had resection of ≥1000 g per breast. Women who had >1000 g of tissue resected per breast had lower risk of developing hypertrophic scar (OR 0.07; 95% CI 0.02-0.25; p < 0.001) and surgical site infection (OR 0.17, 95% CI 0.07-0.42, p < 0.001) than those who had <1000 g of breast resection. No statistical difference was observed among the groups for the outcomes of delayed wound healing and dehiscence, hematoma, fat or areolar necrosis, overall complications rates, and seroma.
Conclusion: Among women who underwent reduction mammoplasty, resection of >1000 g of tissue per breast was associated with lower risk of hypertrophic scar development and surgical site infection than resection of <1000 g.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bjps.2024.11.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Choroidal metastases from thoracic cancer: a retrospective study on clinical characteristics and treatment efficacy.
Front Med (Lausanne)
February 2025
Center of Optometry, Department of Ophthalmology, Peking University People's Hospital, Institute of Ophthalmic and Optometric Medicine, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Optometry School of Peking University Health Science Center, Beijing, China.
Objective: This study aimed to examine the clinical characteristics of choroidal metastases (CMs) and assess the efficacy of various treatment strategies for CMs in a specific patient cohort.
Methods: This retrospective case series study included 32 patients (38 eyes) diagnosed with CM at the Department of Ophthalmology, Peking University People's Hospital, between 2009 and 2022. The cohort included 10 male patients (10 eyes) and 22 female patients (28 eyes), with a mean age of 52.
CRISPR/Cas9 Targeting of Aldehyde Dehydrogenase 1A1 Reveals Heterogeneous Roles in Radiation Response and Redox Stress Across Clonal Lines in Triple-Negative Breast Cancer.
Int J Mol Sci
March 2025
Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute, ChristianaCare, 4701 Ogletown Stanton Rd Suite 4300, Newark, DE 19713, USA.
The metabolic enzyme aldehyde dehydrogenase 1A1 (ALDH1A1), a cancer stem cell marker associated with poor outcomes in breast cancer, has emerged as a promising therapeutic target in TNBC. The aim of this study was to investigate the role of ALDH1A1 in radiation resistance and redox stress in triple negative breast cancer (TNBC). Functional knockouts of ALDH1A1 were generated by the CRISPR/Cas9-mediated deletion of ALDH1A1 in the SUM159 cell line, and three distinct clonal populations were isolated.
View Article and Find Full Text PDFHypoxia Modulates Transmembrane Prostatic Acid Phosphatase (TM-PAP) in MCF-7 Breast Cancer Cells.
Int J Mol Sci
February 2025
Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-901, Brazil.
In MCF-7 breast cancer cells, transmembrane prostatic acid phosphatase (TM-PAP) plays a critical role in tumor progression, particularly under hypoxic conditions. In this study, the impact of hypoxia on ectophosphatase activity in MCF-7 cells was examined, and the underlying biological mechanisms that influence the breast cancer microenvironment were explored. Compared with normoxic cells, hypoxic cells presented significant reductions in ectophosphatase activity, indicating that hypoxia altered dephosphorylation processes critical for tumor growth and metastasis.
View Article and Find Full Text PDFTumor Regulatory Effect of 15-Hydroxyprostaglandin Dehydrogenase (HPGD) in Triple-Negative Breast Cancer.
Int J Mol Sci
February 2025
Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC 20037, USA.
Prostaglandin regulation is known to play a pivotal role in tumorigenesis; however, the contributions of the prostaglandin-metabolizing enzyme 15-hydroxyprostaglandin dehydrogenase (HPGD) to cancer development remain poorly understood. In this study, we investigate the effects of HPGD on cell viability, proliferation, anchorage-independent growth, and migration in triple-negative breast cancer (TNBC), an aggressive subtype of breast cancer. Overexpression of HPGD in human TNBC cells resulted in both positive and negative regulation of cell proliferation and colony formation, with these effects occurring independent of prostaglandin E2 (PGE).
View Article and Find Full Text PDFThe Role of Ferulic Acid in Selected Malignant Neoplasms.
Molecules
February 2025
Faculty of Chemical and Process Engineering, Warsaw University of Technology, Waryńskiego 1, 00-645 Warszawa, Poland.
Ferulic acid (FA) is a polyphenol that is found in plants and fruits. It has a wide range of anticancer properties, including participating in cell apoptosis, inhibiting invasion and angiogenesis, and acting synergistically with standard cytostatic agents in malignant tumors. A range of molecular mechanisms are involved in anticancer activity and include the following ones: activation of cell-cycle-related proteins and enzymes such as p53, p21, Bax, and pro-caspases 3 and 9, reduction of cyclin D1 and E, proapoptotic Bcl-2, MMP-9, and NF-kV, which decrease VEGF, leading to cell cycle arrest at G0/G1 phase and death of cancer cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!